Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

@article{Sun2015AntiCD20CD3TC,
  title={Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies},
  author={L. Sun and D. Ellerman and M. Mathieu and Maria Hristopoulos and Xiaocheng Chen and Yijin Li and Xiaojie Yan and Robyn Clark and A. Reyes and E. Stefanich and E. Mai and Judy C. Young and C. Johnson and Mahrukh A. Huseni and Xinhua Wang and Yvonne Chen and Peiyin Wang and H. Wang and N. Dybdal and Y. Chu and N. Chiorazzi and J. Scheer and T. Junttila and K. Totpal and M. Dennis and A. Ebens},
  journal={Science Translational Medicine},
  year={2015},
  volume={7},
  pages={287ra70 - 287ra70}
}
Anti-CD20/CD3 T cell–dependent bispecific antibodies may be useful for the treatment of B cell malignancies. Two-headed cancer therapy Immunotherapeutic approaches harness either humoral (antibody-mediated) or cellular (T cell–mediated) immunity to fight cancer. Sun et al. combine these approaches by designing a CD3/CD20 TDB (T cell–dependent bispecific), a dual-targeted antibody that recruits T cells to CD20-expressing cells. Their humanized TDB induces T cells to kill primary patient leukemia… Expand
Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer
TLDR
The nonclinical pharmacology of anti-LYPD1/CD3 T-cell-dependent bispecific antibody (TDB) is generally well tolerated at high-dose levels in mice, a pharmacologically relevant species, and showed no evidence of toxicity or damage to LYPD1 expressing tissues. Expand
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies
TLDR
Unlike CD28 superagonists, which broadly activate T cells and resulted in profound toxicity in early clinical trials, these TSAxCD28 bispecifics show limited activity and no toxicity when used alone in genetically humanized immunocompetent mouse models or in primates. Expand
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation
TLDR
Trispecific antibodies that recognize CD38, CD3 and CD28 and induce T cell activation and co-signaling are developed and shown in mice and non-human primates that by engaging multiple targets, these antibodies induce enhanced tumor-cell killing. Expand
IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody
TLDR
The results suggest that anti-HER2/CD3 TDB may be efficacious in patients and indications that respond poorly to checkpoint inhibitors and an active T-cell recruitment mediated by TDB-induced chemokine signaling was the major mechanism for T- cell recruitment. Expand
T Cell–Activating Bispecific Antibodies in Cancer Therapy
TLDR
Bispecific Abs are an emerging cancer immunotherapy approach seeking to re-engage either T effectors or NK cells with malignant cells to build an immunologic synapse and induce tumor cell killing. Expand
An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
TLDR
The data suggest that an appropriately engineered CLL-1 TDB could be effective in the treatment of AML, and the design, discovery, pharmacologic activity, pharmacokinetics, and safety are suggested. Expand
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
TLDR
Data from in vitro and in vivo experiments support investigation of CD19/CD3 bsAb's and other T cell-recruiting bs Ab's as immunotherapies for CLL, especially in combination with ibrutinib or as rescue therapy in ibrUTinib-resistant disease. Expand
An anti-CD 3 / anti – CLL-1 bispeci fi c antibody for the treatment of acute myeloid leukemia
• Bispecific antibodies binding CD3 and CLL-1 deplete CLL-1 target cells in animal models. • An appropriately engineered CLL-1/CD3 bispecific antibody could be effective in treating AML. AcuteExpand
Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma.
TLDR
A tetravalent bsAb with bivalent binding specificity for the CD20 and CD3 antigen in an immunoglobulin G (IgG) format is engineered that demonstrates this antibody's highly efficient cancer cell elimination in a dose-dependent manner in a CD20-expressing B lymphoblastoid cell line in vitro. Expand
CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT mice
TLDR
These studies validate the use of BLT humanized mice for the in vivo evaluation and preclinical development of bispecific molecules that redirect human T cells to selectively deplete target cells. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 59 REFERENCES
Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti‐CD20 × anti‐CD3), mediates efficient killing of B‐cell lymphoma cells even with very low CD20 expression levels
TLDR
The new trifunctional antibody, Bi20 (FBTA05, anti‐CD20 × anti-CD3), that connects B cells and T cells via its variable regions and recruits FcγRI+ accessory immune cells through its Fc region may offer new immunotherapeutic options for the treatment of B‐cell lymphomas. Expand
T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16
TLDR
T and NK cells of patients with B cell NHL are fully capable of being activated by therapeutic crosslinking antibodies, providing a rationale for the use of TandAbs for patients withB cell NHL, particularly in cases where remission with minimal residual disease could be achieved by cytotoxic chemotherapy. Expand
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma.
TLDR
The ability of the CD19xTCR DART to inhibit B- cell lymphoma in NOD/SCID mice when coadministered with human PBMCs supports further evaluation of DART molecules for the treatment of B-cell malignancies. Expand
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates
TLDR
Evaluated systemic effects of anti-CD79b antibodies and ADCs in normal animals suggest that targeting CD79b with antibodies or ADCs may provide safe and effective therapies for B-cell malignancies and autoimmune diseases. Expand
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
TLDR
Pro adoptive transfer of T cells genetically modified to express an anti-CD19 chimeric Ag receptor (CAR) has great promise to improve the treatment of B-cell malignancies because of a potent ability to eradicate CD19(+) cells in vivo; however, reversible cytokine-associated toxicities occurred after CAR-transduced T-cell infusions. Expand
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
TLDR
MT110 appears as an attractive bispecific antibody candidate for treatment of human Ep-CAM-overexpressing carcinomas and could eradicate patient-derived metastatic ovarian cancer tissue growing under the skin of NOD/SCID mice. Expand
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
TLDR
The response of lymphocytes in leukemic patients to continuous infusion of blinatumomab helps to better understand the mode of action of this and other globally T cell-engaging Abs. Expand
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.
TLDR
Combining HER2-TDB with anti-PD-L1 yielded a combination immunotherapy that enhanced tumor growth inhibition, increasing the rates and durability of therapeutic response. Expand
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1
TLDR
Data demonstrate that C activation is fundamental for rituximab therapeutic activity in vivo, suggesting that its activity is T cell independent. Expand
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
TLDR
The data show that the class of single-chain bispecific antibodies has very high antitumor efficacy in vivo and can use previously unstimulated T cells at low effector-to-target ratios. Expand
...
1
2
3
4
5
...